Posted inClinical Updates Oncology Respiratory
Evaluating Benmelstobart With or Without Anlotinib as Consolidation Therapy After Chemoradiotherapy in Unresectable Stage III NSCLC: Insights from the R-ALPS Trial
The R-ALPS randomized trial confirms that benmelstobart improves progression-free survival in unresectable stage III NSCLC patients post-chemoradiotherapy, while adding anlotinib does not significantly enhance efficacy and raises severe toxicity risks.